G-CSF (Filgrastim) as an Adjunct to MOPP/ABVD Therapy in Hodgkin's Disease

Gustavsson, Anita

doi:10.3109/02841869709001303

Acta Oncologica

1997

DOI: 10.3109/02841869709001303

|View full text |Cite

G-CSF (Filgrastim) as an Adjunct to MOPP/ABVD Therapy in Hodgkin's Disease

Anita Gustavsson

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2003

2008

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 5 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a small, non‐randomized trial in which 16 G‐CSF‐treated patients with HD were compared with 25 matched historical controls, the use of G‐CSF was associated with significantly higher dose intensity during MOPP/ABVD therapy, but there was no difference in terms of complete response to chemotherapy or survival (Gustavsson, 1997).…”

mentioning

confidence: 99%

Guidelines on the use of colony‐stimulating factors in haematological malignancies

Pagliuca

Carrington

Pettengell³

et al. 2003

Br J Haematol

View full text Add to dashboard Cite

mentioning

confidence: 99%

Guidelines on the use of colony‐stimulating factors in haematological malignancies

Pagliuca

Carrington

Pettengell³

et al. 2003

Br J Haematol

View full text Add to dashboard Cite

Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma

Bohlius

Herbst

Reiser

et al. 2008

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy

Chand¹,

Link²,

Ritchie

et al. 2006

Leukemia & Lymphoma

View full text Add to dashboard Cite

When uncomplicated neutropenia during doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy for the treatment of Hodgkin's lymphoma is encountered, it is unclear whether or not treatment should be modified. In the present study, we determined the incidence of neutropenia, febrile neutropenia, and the relationship of febrile neutropenia to grade III/IV neutropenia and dose modification, in a large university patient population. We reviewed the charts of patients diagnosed with Hodgkin's lymphoma between 1 January 1990 and 31 December 2002 who were treated with ABVD chemotherapy, and seen at the University of Iowa with complete diagnosis, staging, and treatment dosing records. Adequate data was available on 894 treatments in 81 patients with Hodgkin's lymphoma treated with ABVD chemotherapy. Grade III/IV neutropenia was present on the scheduled day of treatment in 187 (20.9%) treatments in 64 (79%) patients. Grade III/IV neutropenia was most common at cycle 1 day 15. Febrile neutropenia developed nine times in eight patients, and eight episodes of febrile neutropenia developed when the treatment-day absolute neutrophil count (ANC) > or =1000. Dose delay of >4 days and/or dose reduction to <80% of original doxorubicin dose following grade III/IV neutropenia occurred in 29 of 187 treatments, with no episodes of febrile neutropenia. With grade III/IV neutropenia on the day of therapy, 158 treatments were administered without dose reduction or dose delay with one subsequent episode of febrile neutropenia. Neutropenia during ABVD is common, and dose modification for uncomplicated neutropenia on the day of treatment may not reduce the risk of febrile neutropenia. It may be possible to maintain dose intensity in the face of uncomplicated neutropenia during ABVD therapy.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

G-CSF (Filgrastim) as an Adjunct to MOPP/ABVD Therapy in Hodgkin's Disease

Cited by 5 publications

References 17 publications

Guidelines on the use of colony‐stimulating factors in haematological malignancies

Guidelines on the use of colony‐stimulating factors in haematological malignancies

Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma

Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy

Contact Info

Product

Resources

About